This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated IL6R Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-IL6R WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~51.5 kDa | |
| Observed band | 52 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | Glycosylated + Cleaved | |
| Caveat | Heavy N-glycosylation | |
| Regulation | IFN-γ-induced | |
| Isoform | 2 isoform(s) |
Literature-validated Western blot parameters for IL6R — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human A549 . After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-IL6R antigen affinity purified polyclonal antibody (Catalog # A01425-1) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for IL6R at approximately 52KD. The expected band size for IL6R is at 52KD |
| Gel % | 10–12% |
| Load | 50ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:10000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 52 kDa |
IL6R has a 51.5 kDa predicted backbone but is observed at about 52 kDa on Western blot, a modest shift driven mainly by its N- and O-linked glycosylation.
| Band at approximately 52 kDa | matches the empirically observed native IL6R band, close to the 51.5 kDa predicted backbone |
| Band running slightly above the 51.5 kDa predicted mass, sometimes appearing diffuse | carbohydrate mass from the five N-linked and one O-linked glycosylation sites adds to the polypeptide backbone |
| Broad or fuzzy band rather than one crisp line | heterogeneous glycan occupancy across the six annotated glycosylation sites produces a mix of glycoforms |
| A second band or doublet at a different apparent size | reflects the two annotated splice isoforms of IL6R, which differ in sequence and membrane topology |
| Little or no band in whole-cell lysate despite protein being present in serum or conditioned media | the secreted/soluble form of IL6R partitions to extracellular fluid rather than the cell pellet used for lysate |
| Mature band slightly smaller than a precursor-sized species | cleavage of the 19-residue N-terminal signal peptide removes mass from the immature precursor to give the mature protein |
| Predicted mass (51.5 kDa, 468 aa) | sets the baseline unmodified backbone size the observed band is compared against |
| N-glycosylation at Asn55, Asn93, Asn221, Asn245, and Asn350 | adds carbohydrate mass that shifts and can broaden the band above the predicted size |
| O-glycosylation at Thr352 | contributes additional heterogeneous mass on top of the N-glycan contribution |
| Signal peptide cleavage (residues 1-19) | the mature processed protein runs slightly smaller than the uncleaved precursor |
| Isoforms 1 and 2 from alternative splicing | can produce a second band or isoform-restricted detection depending on which form a lysate expresses |
| Non-glycosylated bacterial or minimally processed recombinant standard | runs lower than native IL6R because it lacks the added glycan mass |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | the soluble/secreted form of IL6R is released into extracellular fluid rather than retained in whole-cell lysate | test serum or conditioned media alongside lysate, or enrich the membrane fraction for the cell-surface isoform |
| Band higher than expected | N- and O-linked glycosylation adds carbohydrate mass above the 51.5 kDa backbone | treat the sample with PNGase F or a glycosidase and confirm the band shifts toward the predicted mass |
| Broad smear instead of sharp band | heterogeneous occupancy across the six glycosylation sites yields a mixture of glycoforms | deglycosylate the sample or run a longer, lower-percentage gradient gel to resolve a tighter band |
| Multiple bands | co-detection of isoform 1 and isoform 2, or incomplete reduction of the intrachain disulfide bonds | ensure full reduction with fresh reducing agent and compare band pattern to isoform-specific expression controls |
| Fragments below expected size | loss of the N-terminal signal peptide during processing, or proteolytic degradation during lysis | include protease inhibitors during lysis and compare fragment size to the mature versus precursor difference |
| Weak or no signal | IL6R expression is restricted mainly to hepatocytes and immune cells, so unrelated cell types show low abundance | increase total protein loaded or select a lysate from a known IL6R-expressing cell line |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for IL6R, answered from its protein features.
BosterBio's IL6R antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
Our top-performing anti-IL6R antibody is extensively cited and rigorously validated, with specificity confirmed through orthogonal approaches including negative-tissue controls and complementary methods, ensuring confident, reproducible Western blot detection of IL6R across experimental systems.
Which to pick: Only one anti-IL6R antibody is catalogued, A01425-1, backed by an actual Western blot validation image showing specific detection under standard SDS-PAGE conditions—making it the straightforward, well-supported choice for your IL6R Western blot experiments.